In search of potent inhibitors of cholinesterases, we have synthesized and evaluate a number of 2,3-dihydroquinazolin-4(1H)-one derivatives. The synthetic approach provided an efficient synthesis of the target molecules with excellent yield. All the tested compounds showed activity against both the enzymes in micromolar range. In many case, the inhibition of both enzymes are higher than or comparable to the standard drug galatamine. With the selectivity index of 2.3 for AChE, compound 5f can be considered as a potential lead compound with a feature of dual AChE/BChE inhibition with IC50 = 1.6±0.10 µM (AChE) and 3.7±0.18 µM (BChE). Binding modes of the synthesized compounds were explored by using GOLD (Genetic Optimization for Ligand Docking) suit v5.4.1. The computed binding modes of these compounds in the active site of AChE and BChE provide an insight into the mechanism of inhibition of these two enzymes.
Introduction:
Alzheimer's disease (AD) is one of the most common Neurodegenerative Disorders (NDs) and is considered as the reason for almost 60% of the dementia cases among the persons over 65 years of age [1] [2] . AD is a multifactorial disorder that is associated with dementia and memory impairment. Various pathological hypotheses have been put forth to explain the onset and progression of this disease. These include decreased levels of Acetylcholine (ACh) or enhanced activities of acetylcholinesterase (AChEs), amyloid-β (Aβ) deposits, tau (τ)-protein aggregation and oxidative stress. These all hypotheses are based on the biochemical phenomenon found to be happening in the brains of AD patients. Cholinesterases is found to be the only effective therapeutic approach for AD up till now [3] [4] [5] . Hydrochlorides, Phenyl-5,6-dimethoxy-1-oxo-2,3-dihydro-1H-2-indenylmethanone Analogues, and Ladostigil) and many more which are under preclinical and clinical trials [3, [6] [7] .
Quinazoline, a class of fused pyrimidine consists of very useful nitrogen containing heterocyclic moieties which show various biological activities like anticonvulsant and hypnotic, anticancer, antimicrobial and antihistaminic, diuretic, antimalarial, antihypertensive, antagonism of ghrelin receptor, anti-inflammatory, analgesic and COX-2 inhibitory activities as well as antifungal 4 activities [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . On the basis of substitution pattern on central ring of quinazoline, it can be divided into 2-substituted-4(3H)-quinazolinones, 3-substituted-4(3H)-quinazolinones, 2,3-disubstituted-4(3H)-quinazolinones, 4-substituted-quinazolines and 2,4-disubstituted-4(3H)-quinazolinones categories [18] . Of these synthesis of 2-substituted quinazolinones have attracted the chemists because of their wide range of medicinal and biological properties such as antiinflammatory, antihypertensive, antibacterial activity, anticancer and antitumor [19] [20] [21] [22] . Li et al reported the AChE/BChE inhibition of a series of novel 2-(2-indolyl-)-4(3H)-quinazolines derivates in nanomolar range [23] . Uraz et al reported 4(3H)-quinazolinone derivatives as good AChE inhibitors [24] . Similarly, highly potent spacer-modified bivalent quinazolinimines were reported by Chen et al as inhibitors of AChE/BChE [25] .
Recently, we have reported rational design and synthesis of dihydropyrimidine based dual binding site acetylcholinesterase inhibitors [26] . The objective of this study is to discover a new scaffold as inhibitor of cholinesterases. Herein, we reported the synthesis and in vitro bioactivity of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.
Results and discussion

Chemistry
Various chemists have attempted synthesis of a variety of quinazoline derivatives with focus on synthesis of 2-monosubstituted ones. Very few examples for the synthesis of 2,2-disubstituted quinazoline moieties have been recorded in literature due to their low yields, drastic reaction conditions and prolonged reaction times. However, in many cases use of catalytic methodologies as alternatives to condensation methods have provided many benefits to the scaffold synthesis.
Catalytic carbonylation, domino reaction, hydrogen transfer process, use of metals such as iridium, 5 rhodium and palladium also provide mild reaction conditions and high yields [27] [28] [29] . We tried comparatively an inexpensive acid catalysis method for the synthesis of quinazolines. Starting from 2-amino benzamide and ketone, we were able to synthesize 2,3-dihydroquinazolin-4(1H)-one core under acid catalysis (1ml of HNO3/HCl : 3/1) with excellent yield (Scheme 1).
Reflux, 2 min. 
XRD
The structures of the synthesized compounds were also confirmed by single crystal X-ray diffraction studies. Crystallographic structures and data of some represented compounds are presented in Supplementary information (Figure S1-S3 and in Table S -1 and S-2).
In vitro pharmacology
AChE and BChE inhibition assay
The inhibitory potency (IC50 values) of the synthesized compounds against AChE (Electrophorus electricus) and BChE inhibition (equine serum) was evaluated according to the method [26, 30] .
The in vitro results and selectivity index for AChE and BChE inhibition are summarized in Table   1 .
All the synthesized quinazolines showed good to moderate degree of inhibition and the IC50 value of some of compounds are in low micromolar range toward both enzymes. In general, a clear trend appears that the derivatives with 4-choloropheny group at C-2 position of quinazoline ring (3f, 4f
and 5f) possess high AChE/BChE inhibitory activity in their respective series of analogues.
Similarly, compounds with di-isobutyl group (3h, 4h and 5h) also exhibited good inhibition toward both enzymes. Compounds 3a-h with unsubstituted phenyl ring are less potent than their dinitro (4a-h) and dibromo (5a-h) counterparts.
Compounds 4f, 4h, 5b, 5f and 5h were more potent AChE inhibitors than the standard drug Galantamine with IC50 values in the range of 1.6 µM to 3.9 µM. Amongst the dinitro series (4a-h), compound 4f emerged as potent compound with IC50 value of 3.8±0.14 µM. Compound 4h also exhibited good AChE inhibition (IC50 = 3.9±0.17 µM) comparable to that of 4f. Dibromo derivatives (5a-h) emerged as inhibitor as good as their dinitro counterparts. Introduction of [4] [5] [6] [7] [8] chlorophenyl group at C-2 position led to potent compound 5f (IC50 = 1.6±0.10 µM). Methyl and ethyl substituents at C-2 position did not improve the AChE inhibition. However, replacing these substituents by isobutyl /diisobutyl group (5g and 5h) resulted in moderate to good activity.
To evaluate the selectivity profile, IC50 values of the synthesized compounds toward BChE were also determined. As seen from 
Molecular modelling
Molecular modeling studies on AChE and BChE inhibition
For designing the drug and to understand the molecular mechanism of AD, the three dimensional (3D) structure of AChE is essential. X-ray structures of AChE from different species such as
Electrophorus electricus (eel), Torpedo californica (TcAChE), Drosophila melanogaster, human (hAChE) and mouse have been reported in the literature [31] [32] . The structure of TcAChE provide insights into the mechanism of enzyme catalysis. However, recent studies have shown that the binding site of hAChE is different from TcAChE. Therefore, we studied the binding interactions of our synthesized compounds with both the enzymes by using GOLD (Genetic Optimization for Ligand Docking) suit v5.4.1 [33] . The X-ray crystallographic structure of TcAChE (PDB Code 1EVE) and hAChE (PDB Code 4EY7) in complex with donepezil were used as enzyme structures.
In general, visual inspection of the docked compound-enzyme complexes revealed following 
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Superposition of the docked poses of the most active compound 5f into the binding pockets of TcAChE and hAChE is shown in Figure 1a . The binding mode analysis of 5f-TcAChE and 5f-hAChE complex reveals mostly similar binding mode as shown in Figure 1a . Depiction of the top-scored docking pose of the most active compound 5f in the binding site of TcAChE and hAChE is presented in Figure 1a -b. Dibromo phenyl ring is oriented toward Trp84 (Trp86 in hAChE) and engaged in π-π stacking interactions. In TcAChE, two T-shaped orthogonal π-π stacking interactions were observed between chlorophenyl at C-2 and Phe331 and another between same substituent and Tyr334 (Figure 1b) . Bromine atoms interacts with the π-system of Trp84, Tyr130, Phe330, and His440, While, in hAChE-5f complex, chlorophenyl ring is properly packed in the narrow gorge and forms some π-π stacking and π-σ interactions with Tyr337 and Tyr341 respectively. Although, the binding pattern of donepezil in hAChE is different from TcAChE [32] , however, our small molecules bind in same conformation as in TcAChE (Figure 1a) . This was further confirmed by their Gold fitness score values. Gold fitness score for 5f is 72.3148 (TcAChE) and 72.8581 (hAChE). for 2f is 69.6228. Compound 3a is the least active compound with IC50 value of 80.3±1.8 µM.
Compound 3a oriented itself at a distance of 4.36 Å and interacts with Trp84 via π-π stacking 13 interactions (Figure 2b ). This only interaction is considered to be the reason of the very low inhibition of 3a. For gaining insight into the mechanism of BChE inhibition, the X-ray crystallographic structure of human BChE (PDB Code 1P0I) was used as enzyme structure. The most potent BChE inhibitor 5f displayed the most was docked into the active site of HuBChE (1P0I) 
Conclusion
In the light of above findings, it can be concluded that we have synthesized and tested quinazoline derivatives for AChE and BChE inhibitory potency. All the derivatives showed activity against both the enzymes. All the tested compounds showed activity against both the enzymes in micromolar range. In many case, the inhibition of both enzymes are higher than or comparable to the standard drug galatamine. The findings of this study suggest that appropriate structural modification of quinazoline scaffold may result in potential AChE or BChE inhibitors.
Materials and Methods
Analytical grade chemicals obtained from commercial suppliers were used as received. Melting points were measured using a SMP30 Stuart Scientific melting point apparatus. 1 The X-ray diff raction data of crystals was collected on a Bruker Smart APEX II diff ractometer.
Data reduction was carried out using the SAINT program [34] . The structure solution and refinements were performed with the SHELXL-2013 program package [35] . 
Synthesis of 2-methyl-2-phenyl-2,3-dihydroquinazolin-4(1H)-one(3b)
3b was synthesized by general procedure using a mixture of 2-amino benzamide (13.6 g, 100 mmol) and acetophenone (23. The mixture was pre-incubated at 30 °C for 10 min and followed by adding 1mM ATCI or BTCI and incubated again for 15 min. The enzymatic hydrolysis was monitored at 412 nm using µQuant microplate spectrophotometer (MQX200, BioTek USA). All reactions were carried out in triplicate.
The IC50 values were determined by plotting the inhibition against the sample solution concentrations.
Computational studies
Docking studies were carried out using GOLD (Genetic Optimization for Ligand Docking) suit v5.4.1. The X-ray crystallographic structure TcAChE (PDB Code 1EVE) and hAChE (PDB Code 4EY7) and human BChE (PDB Code 1P0I) was used as enzyme structures. The default docking protocol was applied and the synthesized tin complexes were submitted to 10 GA runs using GOLD fitness score. Other docking parameters were set to the software's default values. The view of the docking results and analysis of their surface with graphical representations were done using Discovery Studio Visualizer [36] and Chimera 1.11.2rc [37] .
